Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo
Background: Vitiligo is a chronic disease that is often challenging to treat. Melanocyte destruction in vitiligo is mediated by immune pathways involving IFN-γ and CD8+ T cells. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, can be a promising treatment for vitiligo due to its potential to inhibit...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Wolters Kluwer Medknow Publications
2026-05-01
|
| Series: | Indian Journal of Dermatology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijd.ijd_141_25 |
| Tags: |
No Tags, Be the first to tag this record!
|